Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation.
Jupiter Neurosciences stock last closed at $6.00, up 30.15% from the previous day, and has decreased 93.55% in one year. It has underperformed other stocks in the Biotechnology industry by 0.81 percentage points. Jupiter Neurosciences stock is currently +31.58% from its 52-week low of $4.56, and -95.65% from its 52-week high of $138.00.
At the moment, there are 483,750 shares of JUNS outstanding. The market value of JUNS is $2.90M. In the past 24 hours, 160,000 JUNS shares were traded.
You will need an online brokerage account to access the NASDAQ market and buy JUNS shares.
Based on our research, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked the right brokerage, you need to fill out some personal info so you are able to invest in JUNS today.
Now that you've created your account on apps for stock market, you can securely and quickly fund your account:
Watch this video walkthrough if you need help transferring money into your brokerage account.
Once you have selected the best place to buy Jupiter Neurosciences stock, it's crucial to research their stock before you buy, so you truly wrap your head around the risk as well as the opportunity.
WallStreetZen was built to help everyday investors do better fundamental analysis in less time.
You can see all of the due diligence checks on JUNS's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge JUNS's true value.
You can do more valuation research on JUNS's stock here.
You can dive deeper into what analysts are projecting on the Jupiter Neurosciences stock forecast page.
Last year, JUNS revenue was $40.45k. During the last three year, JUNS's revenue has gone up by -94.61% per year. This was slower than the Biotechnology industry average of 24.86%.
Dive into JUNS's earnings and revenue performance here.
In the past 12 months, insiders at JUNS have not bought or sold any shares.
Research more about who owns JUNS shares here.
No, Jupiter Neurosciences doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
You have two primary options:
Click the Open Trade button and your broker will execute the order.
If you want more help with buying stocks on eToro, click the how to video below:
Now that you own some JUNS stock, you'll want to keep up with your new investment.
Make a watchlist to track the latest developments regarding your JUNS stock.
To reiterate, here are the 6 steps for buying Jupiter Neurosciences stock:
If you are looking for a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Jupiter Neurosciences, create your watchlist below.